Researchers at Stanford University and Biogen faced skeptics head on, challenging the notion that monoclonal antibodies would never serve as therapeutic agents.
Read more about the journey of resilience and innovation:
The road to developing monoclonal antibodies for effectively targeting cancer was paved with tenacity, passion, and strokes of luck.